Issue 10/2019
Content (16 Articles)
Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients
Benoit Milcent, Nathalie Josseaume, Quentin Riller, Ilenia Giglioli, Emilia Rabia, Claire Deligne, Jean-Baptiste Latouche, Mohamad Hamieh, Alexandre Couture, Olivier Toutirais, Yu-Chun Lone, Raphaël Jeger-Madiot, Stéphanie Graff-Dubois, Sandy Amorim, Pascale Loiseau, Antoine Toubert, Pauline Brice, Catherine Thieblemont, Jean-Luc Teillaud, Sophie Sibéril
Desmoid tumors display a strong immune infiltration at the tumor margins and no PD-L1-driven immune suppression
Vasiliki Siozopoulou, Elly Marcq, Julie Jacobs, Karen Zwaenepoel, Christophe Hermans, Jantine Brauns, Siegrid Pauwels, Clément Huysentruyt, Martin Lammens, Johan Somville, Evelien Smits, Patrick Pauwels
Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients
Estefanía Paula Juliá, Pablo Mandó, Manglio Miguel Rizzo, Gerardo Rubén Cueto, Florencia Tsou, Romina Luca, Carmen Pupareli, Alicia Inés Bravo, Walter Astorino, José Mordoh, Claudio Martín, Estrella Mariel Levy
ANTXR1 (TEM8) overexpression in gastric adenocarcinoma makes the protein a potential target of immunotherapy
Masoud Sotoudeh, Ramin Shakeri, Sanford M. Dawsey, Bahareh Sharififard, Naser Ahmadbeigi, Mahmood Naderi
Induction of tumor-specific CD8+ cytotoxic T lymphocytes from naïve human T cells by using Mycobacterium-derived mycolic acid and lipoarabinomannan-stimulated dendritic cells
Yuji Tomita, Eri Watanabe, Masumi Shimizu, Yasuyuki Negishi, Yukihiro Kondo, Hidemi Takahashi
The BRCA2 mutation status shapes the immune phenotype of prostate cancer
Maximilian Jenzer, Peter Keß, Cathleen Nientiedt, Volker Endris, Maximilian Kippenberger, Jonas Leichsenring, Fabian Stögbauer, Josh Haimes, Skyler Mishkin, Brian Kudlow, Adam Kaczorowski, Stefanie Zschäbitz, Anna-Lena Volckmar, Holger Sültmann, Dirk Jäger, Anette Duensing, Peter Schirmacher, Markus Hohenfellner, Carsten Grüllich, Albrecht Stenzinger, Stefan Duensing
Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment
Nicholas Osborne, Rebecca Sundseth, Julian Burks, Hong Cao, Xunxian Liu, Alexander H. Kroemer, Lynda Sutton, Allen Cato, Jill P. Smith
PTPN3 expressed in activated T lymphocytes is a candidate for a non-antibody-type immune checkpoint inhibitor
Akiko Fujimura, Kazunori Nakayama, Akira Imaizumi, Makoto Kawamoto, Yasuhiro Oyama, Shu Ichimiya, Masayo Umebayashi, Norihiro Koya, Takashi Morisaki, Takashi Nakagawa, Hideya Onishi
Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy
Chris D. Zahm, Laura E. Johnson, Douglas G. McNeel
The role of immune infiltrates as prognostic biomarkers in patients with breast cancer
Constantin N. Baxevanis, Michael Sofopoulos, Sotirios P. Fortis, Sonia A. Perez
Unlocking the therapeutic potential of primary tumor-draining lymph nodes
Jossie Rotman, Bas D. Koster, Ekaterina S. Jordanova, A. Marijne Heeren, Tanja D. de Gruijl
Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy
Michael Friedrich, Simon Jasinski-Bergner, Maria-Filothei Lazaridou, Karthikeyan Subbarayan, Chiara Massa, Sandy Tretbar, Anja Mueller, Diana Handke, Katharina Biehl, Jürgen Bukur, Marco Donia, Ofer Mandelboim, Barbara Seliger
T cell engineering for adoptive T cell therapy: safety and receptor avidity
Elvira D’Ippolito, Kilian Schober, Magdalena Nauerth, Dirk H. Busch
Conventional CARs versus modular CARs
Anja Feldmann, Claudia Arndt, Stefanie Koristka, Nicole Berndt, Ralf Bergmann, Michael P. Bachmann
Natural killer cells control metastasis via structural editing of primary tumors in mice
Batya Isaacson, Ofer Mandelboim
“Tumor Immunology Meets Oncology (TIMO) XIV”, May 24–26th 2018, Halle/Saale, Germany
André Steven, Barbara Seliger